Replies to post #99590 on Biotech Values

[ilpapa]

I can't find it easily because I'm a freeloader, but I believe Dew did address (and as I remember, dismiss) the possibility of legal challenge. I reproduced the WSJ quote because I was puzzled by the reaction - tepid, given the importance of the approval for MNTA in this product and others like Copaxone - and wondered whether some might be waiting on clarification of the legal issue.
More likely, perhaps, given the lack of preparation by the analysts at the CC, may be that they felt the need to go back and research the financial implications of the approval for MNTA. Maybe Monday will tell us whether their weekend was spent fruitfully.